Aldeyra Therapeutics, Inc.

The US Food and Drug Administration’s prescription drug user fee goal date calendar for May may be overshadowed by the 31 May goal date for Moderna ’s next-generation COVID-19 vaccine, given a resurg

Despite the ongoing upheaval across the agency, the US Food and Drug Administration maintained its typical reliability when it came to meeting user fee goal dates in the first quarter of 2025, the Pi

Despite a second complete response letter from the US Food and Drug Administration to its new drug application for reproxalap in dry eye disease, Aldeyra expects to refile for approval during the midd

“Pipeline in a pill”-style drug development will be on display in April, when more than half of the user fee goal dates are for new indications on sometimes sprawling labels, as well as one novel biol